Evidence map›Paper›PMID 32665974›Full record

ArticleNPJ Parkinson's disease2020

Current and projected future economic burden of Parkinson's disease in the U.S.

Wenya Yang, Jamie L Hamilton, Catherine Kopil, James C Beck, Caroline M Tanner, Roger L Albin, E Ray Dorsey, Nabila Dahodwala, Inna Cintina, Paul Hogan and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in NPJ Parkinson's disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06899022 (Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease), which is not on this map. Cited by 374 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
374citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06899022 narecruitingnot on this mapstarted 2025, after this paper: background citation

Investigating the Role of Attention in Perceptual and Cognitive Consequences of Parkinson's Disease

TypeinterventionalSponsorUniversity of NebraskaRan2025 to 2028Enrolled138ConditionsEssential Tremor, Parkinson&#39, s Disease (PD), DystoniasArmsNormal therapeutic DBS, Reduced current DBS, Reduced frequency DBS
3 · Its place in the literature

Who cites it

374 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. "Efficacy, safety and certainty of evidence for selective D1/D5 dopamine receptor partial agonists in Parkinson's disease: a systematic review, meta-analysis and GRADE assessment".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Adherence toFrontiers in nutrition · 2025
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Extreme heat and hospitalization with Parkinson's disease among older adults.Journal of exposure science & environmental epidemiology · 2026
    Article
  17. Review
  18. Review
  19. Article
  20. Review

314 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenya YangThe Lewin Group, Falls Church, VA 22042 USA.
Jamie L HamiltonThe Michael J. Fox Foundation, New York, NY 10120 USA.
Catherine KopilThe Michael J. Fox Foundation, New York, NY 10120 USA.
James C BeckParkinson's Foundation, New York, NY 10018 USA.ORCID 0000-0002-4884-9893
Caroline M TannerUniversity of California, San Francisco, CA 94115 USA.ORCID 0000-0002-3775-5082
Roger L AlbinUniversity of Michigan, Ann Arbor, MI 48109 USA.
E Ray DorseyUniversity of Rochester, Rochester, NY 14642 USA.
Nabila DahodwalaPenn Parkinson's Disease and Movement's Disorders Center, Philadelphia, PA 19107 USA.
Inna CintinaThe Lewin Group, Falls Church, VA 22042 USA.
Paul HoganThe Lewin Group, Falls Church, VA 22042 USA.
Ted ThompsonThe Michael J. Fox Foundation, New York, NY 10120 USA.

Funding

Public Outreach and Education CoreP50NS091856 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALBIN, ROGER L · 2014 to 2019
$10.1M
NINDS NIH HHS P50 NS091856
6 · The paper itself

Abstract

Parkinson's disease (PD) is one of the world's fastest growing neurological disorders. Much is unknown about PD-associated economic burdens in the United States (U.S.) and other high-income nations. This study provides a comprehensive analysis of the economic burdens of PD in the U.S. (2017) and projections for the next two decades. Multiple data sources were used to estimate the costs of PD, including public and private administrative claims data, Medicare Current Beneficiary Survey, Medical Expenditure Panel Survey, and a primary survey (

Indexed as

Health care economicsNeurological disorders

Identifiers

PMID32665974
PMCPMC7347582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.